Physician profile
Luke Webb
NPI 1932161916
$287,287.07
in general payments reported to CMS, 2019-2025
41 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $6,302 · 2021: $23K · 2022: $69K · 2023: $57K · 2024: $66K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Travel and Lodging: $10K · Food and Beverage: $8,617 · Consulting Fee: $1,432 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,325.00 |
| Travel and Lodging | $10,341.98 |
| Food and Beverage | $8,617.07 |
| Consulting Fee | $1,432.05 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $239,029.07 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Amgen INC. | $34,889.12 | 2021-2024 | Tezspire |
| Optinose US, INC. | $2,809.47 | 2019-2022 | |
| Genzyme Corporation | $1,925.34 | 2019-2025 | |
| Grifols USA, LLC | $1,514.16 | 2020-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $1,366.07 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Glaxosmithkline, LLC. | $910.44 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Genentech USA, INC. | $712.02 | 2019-2025 | Xolair |
| Csl Behring | $664.57 | 2019-2025 | Haegarda, Hizentra |
| Eli Lilly and Company | $450.00 | 2024 | |
| Biocryst US Sales Co., LLC | $431.88 | 2021-2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $400.79 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $393.08 | 2019-2025 | |
| Pharming Healthcare, INC. | $326.47 | 2021-2025 | Joenja, Ruconest |
| Sanofi-Aventis U.S. LLC | $230.56 | 2021-2024 |
Show all 38 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.